Correction: Differential androgen deprivation therapies with anti-androgens Casodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9(®) lead to promotion versus suppression of prostate cancer metastasis

Benzer Materyaller

• Differential Androgen Deprivation Therapies with Anti-androgens Casodex/Bicalutamide or MDV3100/Enzalutamide versus Anti-androgen Receptor ASC-J9® Lead to Promotion versus Suppression of Prostate Cancer Metastasis
  Yazar:: Lin, Tzu-Hua, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling
  Yazar:: Lin, T-H, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Anti-androgen therapy with Hydroxyflutamide or androgen receptor degradation enhancer ASC-J9(®) enhances BCG efficacy to better suppress bladder cancer progression
  Yazar:: Shang, Zhiqun, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9(®) to Suppress Enzalutamide-resistant Prostate Cancer Progression
  Yazar:: Wang, Ronghao, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients
  Yazar:: Heck, Matthias M., ve diğerleri
  Baskı/Yayın Bilgisi: (2013)